Citius Oncology Plans Stock Offering; Shares Down

MT Newswires Live

2025/07/14

Citius Oncology (CTOR) filed a registration statement Monday for the potential sale of up to $15 million of common shares, and accompanying warrants to buy up to $15 million common shares.

The number of securities and per-share prices were not specified in the filing.

The company said it plans to use the net proceeds to commercialize Lymphir, including milestone, royalty or other payments it has to make under current license deals, and for working capital and general corporate purposes.

The company added that if the offering generates at least $10 million of gross proceeds, it must fully repay the roughly $3.8 million principal due under the August 2024 promissory note issued to Citius Pharmaceuticals (CTXR).

Shares of Citius Oncology fell more than 14% and Citius Pharmaceuticals rose over 4% in recent trading.

Price: 2.53, Change: -0.29, Percent Change: -10.28

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2551182891"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551182891\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551182891?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-14 22:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551182891","market":"sg","top_or_hot":-1,"title":"Citius Oncology Plans Stock Offering; Shares Down","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> (CTOR) filed a registration statement Monday for the potential sale of up to $15 million of common shares, and accompanying warrants to buy up to $15 million common shares.</p><p>The number of securities and per-share prices were not specified in the filing.</p><p>The company said it plans to use the net proceeds to commercialize Lymphir, including milestone, royalty or other payments it has to make under current license deals, and for working capital and general corporate purposes.</p><p>The company added that if the offering generates at least $10 million of gross proceeds, it must fully repay the roughly $3.8 million principal due under the August 2024 promissory note issued to Citius Pharmaceuticals (CTXR).</p><p>Shares of Citius Oncology fell more than 14% and Citius Pharmaceuticals rose over 4% in recent trading.</p><p>Price: 2.53, Change: -0.29, Percent Change: -10.28</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citius Oncology Plans Stock Offering; Shares Down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCitius Oncology Plans Stock Offering; Shares Down\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-14 22:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> (CTOR) filed a registration statement Monday for the potential sale of up to $15 million of common shares, and accompanying warrants to buy up to $15 million common shares.</p><p>The number of securities and per-share prices were not specified in the filing.</p><p>The company said it plans to use the net proceeds to commercialize Lymphir, including milestone, royalty or other payments it has to make under current license deals, and for working capital and general corporate purposes.</p><p>The company added that if the offering generates at least $10 million of gross proceeds, it must fully repay the roughly $3.8 million principal due under the August 2024 promissory note issued to Citius Pharmaceuticals (CTXR).</p><p>Shares of Citius Oncology fell more than 14% and Citius Pharmaceuticals rose over 4% in recent trading.</p><p>Price: 2.53, Change: -0.29, Percent Change: -10.28</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTOR","symbol_name":"CITIUS ONCOLOGY INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2551182891","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551182891","pubTimestamp":1752502296,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Citius Oncology  filed a registration statement Monday for the potential sale of up to $15 million of common shares, and accompanying warrants to buy up to $15 million common shares.The number of securities and per-share prices were not specified in the filing.The company said it plans to use the net proceeds to commercialize Lymphir, including milestone, royalty or other payments it has to make under current license deals, and for working capital and general corporate purposes.The company added that if the offering generates at least $10 million of gross proceeds, it must fully repay the roughly $3.8 million principal due under the August 2024 promissory note issued to Citius Pharmaceuticals .Shares of Citius Oncology fell more than 14% and Citius Pharmaceuticals rose over 4% in recent trading.Price: 2.53, Change: -0.29, Percent Change: -10.28","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTOR":"CITIUS ONCOLOGY INC","BK4007":"制药","BK4139":"生物科技","CTXR":"Citius Pharmaceuticals, Inc."},"translate_title":"Citius Oncology计划发行股票；股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTXR":0.9,"CTOR":0.9},"content_text":"Citius Oncology (CTOR) filed a registration statement Monday for the potential sale of up to $15 million of common shares, and accompanying warrants to buy up to $15 million common shares.The number of securities and per-share prices were not specified in the filing.The company said it plans to use the net proceeds to commercialize Lymphir, including milestone, royalty or other payments it has to make under current license deals, and for working capital and general corporate purposes.The company added that if the offering generates at least $10 million of gross proceeds, it must fully repay the roughly $3.8 million principal due under the August 2024 promissory note issued to Citius Pharmaceuticals (CTXR).Shares of Citius Oncology fell more than 14% and Citius Pharmaceuticals rose over 4% in recent trading.Price: 2.53, Change: -0.29, Percent Change: -10.28","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}